

## MedTech Company STENTiT Raises €1.8 million in Seed Round

Écrit par STENTiT

Mardi, 03 Mai 2022 11:42 - Mis à jour Mardi, 03 Mai 2022 12:31

---

Eindhoven, The Netherlands, 25 April 2022 - [STENTiT](#), a medical device company bringing a novel class of regenerative endovascular implants for the treatment of cardiovascular diseases, has closed a €1.8 million seed investment round. The funding facilitates further pre-clinical development and batch production of a [regenerative stent](#) (see video) for peripheral indications. The investment was made by Dutch investors NextGen Ventures, Brabant Development Agency (BOM) and the Ten Cate Investment Company.

STENTiT is an emerging player in the field of regenerative medical devices, offering a breakthrough solution for cardiovascular interventions by developing first-of-its-kind endovascular implants with regenerative capacity. Using a catheter-based approach, these devices provide the ability to restore arteries without the need for an invasive surgical intervention. The aim is to ultimately restore the affected blood vessel from the inside out to provide a lifelong solution.

As a first target indication, the company wants to improve the treatment of critical limb ischemia. This progressive form of peripheral artery disease affects almost 5 million people in the EU and the US in which the blood flow to the foot is severely being compromised. Unfortunately, current treatment options are ineffective, resulting in amputation within 6 months in 40% of these patients.

With the regenerative stent, blood flow to the foot will be maintained by securing vascular patency using temporary mechanical support and improving long-term efficacy by inducing vascular repair, thereby preventing thousands of amputations each year

Bart Sanders, CEO of STENTiT, said:

*"We are excited to receive the support of these esteemed Dutch early-stage investors. This financing round validates our vision to bring a novel class of implants that can rebuild the affected blood vessels. We are looking forward taking the next steps getting our regenerative stents ready for clinical trials. With our first product, we aim to treat millions of patients suffering from peripheral artery diseases, and save their limbs from amputation"*

## MedTech Company STENTiT Raises €1.8 million in Seed Round

Écrit par STENTiT

Mardi, 03 Mai 2022 11:42 - Mis à jour Mardi, 03 Mai 2022 12:31

---